Gold futures price had been relatively stable in recent days on expectations of more stimuli from the world’s largest economy with a pending USD1 trillion fiscal stimulus package awaiting passage from U.S Congress.

from Yahoo Finance https://ift.tt/31htHSL

Top news and what to watch in the markets on Tuesday, August 4, 2020.

from Yahoo Finance https://ift.tt/3kcmMmL

Shares in cloud communications company RingCentral (RNG) pulled back in Monday’s after-hours trading despite delivering impressive second quarter earning results.Specifically, Q2 Non-GAAP EPS of $0.24 beat Street estimates by $0.04 while GAAP EPS of $0.01 also topped Street forecasts by $0.48. Plus revenue of $278M beat by $14.22M- and represented strong year-over-year growth of 29%.Subscriptions revenue also increased 32% year over year to $257 million and Total Annualized Exit Monthly Recurring Subscriptions (ARR) increased 33% year over year to $1.1 billion.“We delivered solid Q2 results driven again by strong contributions from mid-market and enterprise customers, as well as our channel partners,” cheered Vlad Shmunis, RingCentral’s CEO. “We are seeing a high level of adoption and engagement with our Message Video Phone (MVP) solution as businesses adapt to a work from anywhere environment.”Looking forward, RNG issued robust guidance for the third quarter with 3Q total revenue of $283.5–289.5M (+21% to +24% y/y) which fell above the $283M consensus estimate. Guidance for subscriber revenue of $263–265M (+25% to +26% y/y) beat the $260M consensus estimate with PF operating margin of 10.0–10.2% is and PF EPS of $0.24.For the full year, RNG raised total revenue range to $1.135 to $1.143B, representing annual growth of 26% to 27%. This is up from its prior range of $1.116 to $1.125B and annual growth of 24% to 25%.Overall the stock shows a bullish Strong Buy Street consensus with an average analyst price target of $306. With shares up a whopping 80% year-to-date, the price target now lies flat with the current share price.Following the report Oppenheimer analyst Brian Schwartz reiterated his buy rating on the stock with a price target of $330. “The quarter displayed record new customer adds and big deals ($1M+ TCV), and robust ARR growth, channel demand, and cash flow” he told investors.“Negatively, guidance implies some growth deceleration in the 2H:2020, but we advise investors to look through it given the strengthening fundamentals and with the near-term estimates mostly de-risked” he wrote, adding that work-from-home is only part of a multi-year secular growth driver in cloud business communications. (See RNG stock analysis on TipRanks).Related News: Apple Snaps Up Canadian Payment Startup Mobeewave For $100M – Report Microsoft Confirms TikTok Purchase Talks Back On Table After Trump Call Twitter Reveals FTC Fine Could Hit $250M; Analysts Stay Sidelined More recent articles from Smarter Analyst: * Varonis Up 7% As Earnings Confirm ‘Strong Fundamental Opportunity’ * Gaia Delivers Strong Earnings Beat; Analyst Sees 70% Upside Ahead * Five9 Continues Winning Streak With Strong Q2 Earnings * Alphabet Issues $10 Billion Bond At Low Borrowing Costs

from Yahoo Finance https://ift.tt/33shNIu

Ford Motor Company's (NYSE: F) outlook for the second half of the year remains "mixed but reasonable," according to Morgan Stanley.The Ford Analyst: Analyst Adam Jonas maintained an Overweight rating on Ford and established a price target of $8.Takeaways On Ford: The analyst named these takeaways from Morgan Stanley's conference call with Ford in a Friday note: Cash burn was better-than-expected. The second-quarter cash flow was negative $5.3 billion, but expected cash burn was $12 billion. Ford also finished up its second quarter with $40 billion in gross liquidity."We were pleasantly surprised that the company gave even the basic level of quarterly granularity to its 3Q and 4Q earnings outlook," the analyst said, characterizing the outlook as stable. View more earnings on FWhen Ford CEO Jim Hackett was asked about battery IP risk, he said the challenges include supply chain issues and litigation, according to Morgan Stanley. "We're hopeful that, that gets settled quickly. It really doesn't matter to us how it gets settled, but it may — it confuses some of the suppliers about their investments in some of their plants here in the United States," Hackett said. Jonas said Ford has more room for improvement in its operating performance than any other original equipment manufacturer in Morgan Stanley's coverage.F Price Action: Ford shares were up 0.76% at $6.66 at last check Monday. Photo courtesy of Ford. Latest Ratings for F DateFirmActionFromTo Jul 2020Credit SuisseMaintainsNeutral Jul 2020BarclaysMaintainsEqual-Weight Jul 2020UBSMaintainsNeutral View More Analyst Ratings for F View the Latest Analyst RatingsSee more from Benzinga * 4 Takeaways On Pinterest's Q2 Print * Why BofA Is Turning Bullish On Retailer At Home * Dunkin' Brands Analyst Says Q2 Positives Outweigh The Negatives(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

from Yahoo Finance https://ift.tt/3kbHtPt

The shares of Alterity Therapeutics Ltd. (NASDAQ: ATHE) advanced in the after-hours session trading in New York on Monday and in the regular session in Sydney on Tuesday.What Happened: The surge came as Alterity Therapeutics reported positive data from an animal testing of ATH434 — its leading drug candidate for Multiple System Atrophy, a Parkinsonian disorder.The new data "independently confirm and extend previous findings demonstrating that ATH434 reduces α-synuclein pathology, preserves neurons, and improves motor performance," Alterity Therapeutics noted.Why It Matters: The Melbourne-based pharmaceutical company in June said it had reached an agreement with the United States Food and Drug Administration on the non-clinical investigations required to support the second phase of its clinical trial of ATH434.The FDA had also agreed on the company's design for the Phase 2 study, it claimed.What's Next: Alterity Therapeutics noted that the data from the latest study will be presented at the 2020 International Congress of Parkinson's Disease and Movement Disorders in September and at the American Neurological Association's 2020 Annual Meeting in October.Price Action: The company's shares closed 38.24% up at $0.034 in Sydney on Tuesday, with an intraday high of $0.041.Alterity Therapeutics shares closed 10.37% higher at $1.49 in the after-hours session in New York on Monday. See more from Benzinga * Prescription Drug Prices Tracker, Telehealth Platform GoodRx Files For IPO: Report * Huawei Becomes The World's Largest Smartphone Supplier As China Sales Remain High During Pandemic * Tesla Under Probe In South Korea For Supposed Issues With Autopilot, Other Braking, Steering Systems(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

from Yahoo Finance https://ift.tt/2PqHwIY

Alpha Pro Tech, Ltd.'s (NYSEMKT:APT) price-to-earnings (or "P/E") ratio of 45.6x might make it look like a strong sell…

from Yahoo Finance https://ift.tt/30qe4ZX

from Yahoo Finance https://ift.tt/39UUacN

Regeneron Pharmaceuticals Inc (REGN) has revealed that its investigational COVID-19 antibody drug combination REGN-COV2 both prevented and treated the disease in monkeys and hamsters, says Reuters- an encouraging sign that the drug will also be effective in treating humans.According to the report, Regeneron stated that the double antibody cocktail was able to “almost completely block establishment of virus infection.” The study, which involved 36 monkeys and 50 hamsters, has not yet been peer reviewed.Regeneron also added that REGN-COV2 minimized infection in a second study with a much higher level of the virus- and that the results matched or exceeded animal studies of vaccine candidates.Moreover, the animals did not show increased viral load or worsening of pathology after treatment, indicating that it will not worsen symptoms in humans, Reuters reports.Clinical human trials of REGN-COV2 began in mid-June and the clinical program currently consists of three ongoing late-stage trials, including a Phase 3 trial for the prevention of COVID-19 in uninfected people who are at high-risk of exposure to a COVID-19 patient.“We are running simultaneous adaptive trials in order to move as quickly as possible to provide a potential solution to prevent and treat COVID-19 infections, even in the midst of an ongoing global pandemic,” said George D. Yancopoulos, CEO of Regeneron.The Phase 3 prevention trial is being jointly conducted with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).In the run-up to finding a treatment against COVID-19, shares in Regeneron have skyrocketed 72% so far this year. As a result the $635 average price target now indicates 2% downside potential in the coming 12 months.Oppenheimer analyst Hartaj Singh recently raised the stock’s price target to $675 from $625 and maintained a Buy rating, saying that the company is one of his top biotech names, characterized by ongoing product launches, commercial execution, OPEX control, and a best-in-breed pipeline.“We believe this quality biotech name deserves a higher multiple,” Singh told investors. “Given COVID-19 effects on sales and clinical trial follow-through lacking in FY20 visibility, we caution that further performance could be accompanied by greater volatility. We view sustained weakness as a buying opportunity.”Overall, the rest of the Street is cautiously optimistic on the stock. The Moderate Buy consensus breaks down evenly between 9 Buys and 6 Holds. (See Regeneron stock analysis on TipRanks).Related News: GW Pharma Scores New FDA Approval For CBD Drug Epidiolex Incyte, MorphoSys Win FDA Nod For ‘Key Revenue Driver’ Tafasitamab Moderna Could Charge $50-$60 Per Covid-19 Vaccine Course- Report More recent articles from Smarter Analyst: * Five9 Continues Winning Streak With Strong Q2 Earnings * Alphabet Issues $10 Billion Bond At Low Borrowing Costs * Plug Power Spikes A Further 19% On Major UK Supermarket Deal * Mosaic Rises 7% In After-Market As 2Q Earnings Top Estimates

from Yahoo Finance https://ift.tt/2PzUxQV

from Yahoo Finance https://ift.tt/2EHAopz

There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two…

from Yahoo Finance https://ift.tt/33nQYoI